Cargando…
Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
The ataxia telangiectasia mutated serine/threonine kinase (ATM)/checkpoint kinase 2 (CHEK2, best known as CHK2) and the ATM and Rad3-related serine/threonine kinase (ATR)/CHEK1 (best known as CHK1) cascades are the 2 major signaling pathways driving the DNA damage response (DDR), a network of proces...
Autores principales: | Manic, Gwenola, Obrist, Florine, Sistigu, Antonella, Vitale, Ilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905354/ https://www.ncbi.nlm.nih.gov/pubmed/27308506 http://dx.doi.org/10.1080/23723556.2015.1012976 |
Ejemplares similares
-
Trial Watch: Proteasomal inhibitors for anticancer therapy
por: Obrist, Florine, et al.
Publicado: (2014) -
Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017) -
The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition
por: Mattiello, Luca, et al.
Publicado: (2021) -
Chloroquine and hydroxychloroquine for cancer therapy
por: Manic, Gwenola, et al.
Publicado: (2014) -
Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)